AusPAR: Vortioxetine hydrobromide

Australian Public Assessment Report

AusPAR

AusPAR: Vortioxetine hydrobromide [PDF, 1.47 MB]

AusPAR: Vortioxetine hydrobromide [Word, 3.49 MB]

Attachment: Product Information: Vortioxetine hydrobromide [PDF, 290 KB]

Attachment: Product Information: Vortioxetine hydrobromide [Word, 106.09 KB]

Attachment: Extract from Clinical Evaluation Report: Vortioxetine hydrobromide [PDF, 2.03 MB]

Attachment: Extract from Clinical Evaluation Report: Vortioxetine hydrobromide [Word, 4.83 MB]

Device/Product Name

Brintellix

Active ingredients

Vortioxetine hydrobromide

AusPAR Date

8 July 2014

Published

4 August 2014

Submission Number

PM-2012-03463-1-1

Submission Type

New chemical entity

Decision

Approved

This webpage on the TGA website was printed on 12 Sep 2024. Printed content may be out of date. For up-to-date information, always refer to the digital version: https://www.tga.gov.au/resources/auspar/auspar-vortioxetine-hydrobromide

Sub menu

AusPAR: Vortioxetine hydrobromide

Help us improve the Therapeutic Goods Administration site